📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: “Our continued investment in infrastructure reflects our commitment to delivering innovative and accessible T cell therapies,” said Dr. Ryan Saadi, @CEO_TEVOGEN_BIO. “This facility has potential to efficiently scale our

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: ▪ Advanced algorithms aim to reduce trial planning timelines, accelerating time-to-market for new therapies.▪ Initiative to support Tevogen Bio’s ExacTcell™ pipeline with a goal of enhancing commercial viability and

#𝐈𝐂𝐘𝐌𝐈.📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: . “Through the development and utilization of the PredicTcell platform we have uncovered new insights and are able to quickly analyze significantly larger datasets, potentially resulting in better accuracy and

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: $TVGN #affordable #accessible #celltherapy #AI #ArtificialIntelligence @Microsoft @databricks . · s model drastically reduces target analysis and has the potential to generate billions in cost savings

RT @CEO_TEVOGEN_BIO: Tevogen Meets Wall Street: A Shared Vision of Health and Prosperity. $TVGN #Health #prosperity

RT @NJBIZ: Dr. Ryan Saadi, @TevogenBio founder and CEO, gifts $500,000 for the build-out and first-year operating costs of the company's ex….

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: Completed ahead of schedule, the new facility is designed to anticipate growth as it more than doubles Tevogen’s previous footprint and brings research, regulatory, and the expanding teams together

RT @CEO_TEVOGEN_BIO: Those nights still return—the memory of sitting silently beside hospital beds, holding the hands of young parents who….

⏳ 𝐓𝐞𝐯𝐨𝐠𝐞𝐧 𝐓𝐢𝐦𝐞 𝐂𝐚𝐩𝐬𝐮𝐥𝐞 ⏳. Mittul Mehta CIO and Head of in conversation with @bradmehl of @futuresights_hq and @Medium about AI Innovation in Drug Discovery. 👉. "One of the most interesting use cases that we deal

🎇Happy 4th of July from Team Tevogen!🎇. $TVGN

𝐓𝐰𝐨 𝐞𝐧𝐞𝐫𝐠𝐢𝐳𝐢𝐧𝐠 𝐝𝐚𝐲𝐬 𝐚𝐭 𝐭𝐡𝐞 @CMSGov 2025 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 #𝐂𝐌𝐒𝐐𝐮𝐚𝐥𝐂𝐨𝐧2025. Reflecting on the event, Tevogen’s Head of Government Affairs and Patient Access, David Banko, commented “@DrOzCMS “Make America Healthy Again” fireside

⏳ 𝐓𝐞𝐯𝐨𝐠𝐞𝐧 𝐓𝐢𝐦𝐞 𝐂𝐚𝐩𝐬𝐮𝐥𝐞 ⏳ . Tevogen Bio's positive proof-of-concept clinical trial. Learn more about the results at: $TVGN #affordable #accessible #celltherapy #clinicaltrials @BloodAdvances

RT @CEO_TEVOGEN_BIO: Tevogen: 300+ years of experience in drug development, commercialization, investment banking, & the emerging field of….

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: 𝐂𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩’𝐬 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐨𝐟 𝐭𝐡𝐞 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐜𝐞 𝐀𝐈 𝐰𝐢𝐥𝐥 𝐩𝐥𝐚𝐲 𝐢𝐧 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲. “This personal investment by our CEO

RT @CEO_TEVOGEN_BIO: Growth follows when passion drives. Tevogen’s new HQ—ahead of schedule—designed to meet pace of growth — of @TevogenAI….

⏳ 𝐓𝐞𝐯𝐨𝐠𝐞𝐧 𝐓𝐢𝐦𝐞 𝐂𝐚𝐩𝐬𝐮𝐥𝐞 ⏳. Tevogen's CIO and Head of @TevogenAI speaks to untapped potential and development of a new class of T Cell therapies for large patient populations and overcoming CAR-T challenges at Longwood Spring MIT Conference. $TVGN #affordable

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: “The mechanisms behind EBV-induced tumorigenesis, which includes the disruption of cellular pathways and the promotion of malignant growth by EBV proteins, have become increasingly clear in recent years,” said Neal

🎬 𝐓𝐞𝐯𝐨𝐠𝐞𝐧 𝐁𝐢𝐨 𝐋𝐢𝐯𝐞 𝐟𝐫𝐨𝐦 @Nasdaq 𝐌𝐚𝐫𝐤𝐞𝐭𝐒𝐢𝐭𝐞.Dr. Neal Flomenberg, Chief Scientific Officer, and Lori Grosso, Clinical Development Lead, discussed Tevogen Bio's goal of making cytotoxic #Tcell #immunotherapy a #mainstream, outpatient treatment. $TVGN